Premium
Therapeutic innovations in inflammatory bowel diseases
Author(s) -
Vanhove W,
Nys K,
Vermeire S
Publication year - 2016
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.286
Subject(s) - inflammatory bowel disease , medicine , inflammatory bowel diseases , disease , therapeutic approach , pathogenesis , bioinformatics , immune system , inflammation , crohn's disease , immunology , intensive care medicine , computational biology , biology
Inflammatory bowel disease (IBD) is a spectrum of complex multifactorial immune disorders characterized by chronic inflammation of the gut. Significant advances have been made in unraveling the pathogenesis of this disease spectrum, which have spurred the discovery of new therapeutic targets and strategies. In this review, we highlight the emerging new classes of IBD therapeutics under clinical evaluation and their method of action, including JAK inhibitors, anti‐SMAD7 oligonucleotides, and cell‐based therapies. Moreover, we discuss how an approach based on unique molecular insights in a given patient will, in the future, lead to a truly individualized/tailored disease management, starting at diagnosis, aiding in prognosis, and resulting in a personalized therapeutic approach.